Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.

Authors:
Yu C; Jiang L; Yang D; Dong X; Yu R and 1 more

Journal:
Onco Targets Ther

Publication Year: 2022

DOI:
10.2147/OTT.S380615

PMCID:
PMC9575589

PMID:
36262804

Journal Information

Full Title: Onco Targets Ther

Abbreviation: Onco Targets Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors report no conflicts of interest in this work."

Evidence found in paper:

"This study was supported by the National Natural Science Foundation of China (No. 81672969, 81472814), a grant from the Health scientific and technological achievements and appropriate technology promotion project of Beijing Municipal Health Commission."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025